Urovant Sciences Ltd (NASDAQ:UROV) Short Interest Update

Urovant Sciences Ltd (NASDAQ:UROV) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 795,200 shares, a growth of 5.2% from the August 30th total of 755,700 shares. Based on an average daily volume of 37,200 shares, the short-interest ratio is currently 21.4 days. Currently, 10.9% of the company’s shares are short sold.

A number of brokerages recently issued reports on UROV. HC Wainwright reiterated a “buy” rating and issued a $28.00 price target on shares of Urovant Sciences in a report on Monday, September 9th. ValuEngine upgraded Urovant Sciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $21.63.

Urovant Sciences stock opened at $9.43 on Thursday. The business has a fifty day moving average of $9.49 and a two-hundred day moving average of $8.54. The company has a quick ratio of 6.20, a current ratio of 6.20 and a debt-to-equity ratio of 0.29. The firm has a market cap of $282.17 million and a P/E ratio of -2.13. Urovant Sciences has a twelve month low of $4.05 and a twelve month high of $14.49.

Urovant Sciences (NASDAQ:UROV) last posted its earnings results on Tuesday, August 13th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.02). Equities analysts expect that Urovant Sciences will post -4.02 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the business. Marshall Wace North America L.P. purchased a new stake in Urovant Sciences during the first quarter worth $49,000. Northern Trust Corp lifted its holdings in Urovant Sciences by 55.8% during the second quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock worth $136,000 after buying an additional 6,144 shares during the period. Marshall Wace LLP purchased a new stake in Urovant Sciences during the first quarter worth $325,000. Vanguard Group Inc. lifted its holdings in shares of Urovant Sciences by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 131,487 shares of the company’s stock valued at $1,040,000 after purchasing an additional 9,000 shares during the last quarter. Finally, Sio Capital Management LLC lifted its holdings in shares of Urovant Sciences by 2.3% during the 2nd quarter. Sio Capital Management LLC now owns 220,042 shares of the company’s stock valued at $1,741,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors own 24.10% of the company’s stock.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Featured Article: Calculating net profit and net profit margin ratio

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.